Atossa Therapeutics, Inc. Common Stock (ATOS) is a publicly traded Healthcare sector company. As of November 10, 2026, ATOS trades at $2.14 with a market cap of $21.16M and a P/E ratio of -0.58. ATOS moved +0.47% today. Year to date, ATOS is -77.43%; over the trailing twelve months it is -82.65%. Its 52-week range spans $1.70 to $19.35. Analyst consensus is buy with an average price target of $17.50. Rallies surfaces ATOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Atossa sets CVR terms as Q3 loss narrows and clinical milestones approach: Atossa will distribute one stapled CVR for each common share outstanding as of October 19, 2026, or issued thereafter; holders may collectively receive 25% of net proceeds from monetizing the first qualifying FDA priority review voucher, capped at $50 million. The third-quarter net loss narrowed 35% year over year to $5.64 million, and Atossa has clinical milestones scheduled through 2027.
| Metric | Value |
|---|---|
| Price | $2.14 |
| Market Cap | $21.16M |
| P/E Ratio | -0.58 |
| EPS | $-4.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.35 |
| 52-Week Low | $1.70 |
| Volume | 159 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-34.77M |
| Gross Margin | 0.00% |
2 analysts cover ATOS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.50.